Comparative Pharmacology
Head-to-head clinical analysis: CEPHAPIRIN SODIUM versus CLAFORAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEPHAPIRIN SODIUM versus CLAFORAN.
CEPHAPIRIN SODIUM vs CLAFORAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cephapirin sodium is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), primarily PBP1 and PBP3, thereby inhibiting transpeptidation and disrupting peptidoglycan cross-linking, leading to cell lysis mediated by autolytic enzymes.
Cefotaxime is a bactericidal cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking.
500 mg to 1 g IM or IV every 6 hours.
1-2 g IV/IM every 8 hours. Maximum dose: 12 g/day in divided doses.
None Documented
None Documented
0.5-1.0 hours; prolonged to 2-5 hours in renal impairment, requiring dose adjustment.
0.8-1.4 hours in normal renal function (prolonged to 11-30 hours in severe renal impairment, CrCl <10 mL/min). No clinically relevant accumulation with standard dosing in renal impairment with dose adjustment.
Renal: 80-90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <5%.
Primarily renal (80-90% unchanged in urine via glomerular filtration and tubular secretion); biliary/fecal <10%.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic